Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Company Overview

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Key Stats

• Today's Range: $0.32 to $0.33
• 50-Day Range: $0.32 to $0.90
• 52-Week Range: $0.19 to $1.58
• Volume: 208,804 shs
• Average Volume: 4.97 million shs
• Market Capitalization: $5.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

Kazia Therapeutics Stock Analysis - MarketRank™

Kazia Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kazia Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kazia Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.

Price to Book Value per Share Ratio

Kazia Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.01% of the outstanding shares of Kazia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kazia Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kazia Therapeutics has recently decreased by 21.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kazia Therapeutics does not currently pay a dividend.

Dividend Growth

Kazia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.01% of the outstanding shares of Kazia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kazia Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kazia Therapeutics has recently decreased by 21.75%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

12 people have searched for KZIA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

2 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Kazia Therapeutics is held by insiders.

Percentage Held by Institutions

Only 30.89% of the stock of Kazia Therapeutics is held by institutions.

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed this year?

Kazia Therapeutics' stock was trading at $0.4395 at the start of the year. Since then, KZIA stock has decreased by 26.1% and is now trading at $0.3247.
View the best growth stocks for 2024 here.

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP) and Pfizer (PFE).

Company Calendar

• Today: 9/20/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZIA
• CUSIP: N/A
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +505.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $20,000.00
• Price / Sales: 270.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 16,341,000
• Free Float: 16,178,000
• Market Cap: $5.40 million
• Optionable: Optionable
• Beta: 2.13